CytoDyn Inc. (CYDY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

CytoDyn Inc. (CYDY) is down 5.8% since the beginning of the year. At $0 per share, CYDY is trading 33.6% below its 52-week high of $0. Investors who bought $1,000 worth of CYDY shares 5 years ago would now be looking at an investment worth $158.

CytoDyn Inc. (CYDY) has returned -5.79% so far this year and -14.90% over the past 12 months. Over the last ten years, CYDY has returned -13.84% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jul 16, 2007, CYDY's average daily return is +0.32%, while the average monthly return is +3.37%. At this rate, an investment would double in approximately 1.7 years.

Historically, 42% of months were positive and 58% were negative. The best month was Dec 2019 with a return of +257.1%, while the worst month was Nov 2007 at -66.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CYDY closed higher 36% of trading days. The best single day was Aug 11, 2009 with a return of +142.9%, while the worst single day was Jun 25, 2008 at -66.7%.

CytoDyn Inc. has an annualized alpha of 120.93%, beta of 0.01, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 16, 2007.

• This stock participated in 124.70% of S&P 500 Index downside but only 68.10% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.01 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CYDY ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CytoDyn Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CytoDyn Inc. was 98.76%, occurring on Dec 5, 2024. The portfolio has not yet recovered.

The current CytoDyn Inc. drawdown is 96.99%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CytoDyn Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CytoDyn Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.